IC
NAMS icon

Ikarian Capital’s NewAmsterdam Pharma NAMS Stock Holding History

Ikarian Capital’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6M Buy
+400,000
New +$13.2M 1.46% 18

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Ikarian Capital's NAMS Position: Q1 2026 in Review

Ikarian Capital sold out of NewAmsterdam Pharma (NAMS) in Q1 2026, closing a stake of 45,830 shares — an estimated $1.61M sold.

Ikarian Capital first reported a position in NAMS in Q2 2025 and held it in 3 quarters. The position peaked at $3.75M in Q2 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Ikarian Capital reported no remaining NewAmsterdam Pharma position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 45,830 NewAmsterdam Pharma shares in Q1 2026, an estimated $1.61M.
  • Ikarian Capital first reported a position in NewAmsterdam Pharma in Q2 2025 and held it in 3 quarters.
  • Ikarian Capital's NewAmsterdam Pharma position peaked at $3.75M in Q2 2025.
  • 171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.